News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah, discusses new treatments for HR+/HER2- breast cancer and immunotherapy challenges, ...

An adjuvant is a substance that is added to a vaccine to enhance the vaccine's efficacy. Adjuvants can, for example, stimulate the immune response to the antigen in the vaccine or stabilize the ...

This important study demonstrates a potential mechanism by which adjuvants influence T-cell responses. The observation that adjuvant impacts the exogenous peptide repertoire presented by MHC II ...

Basel: This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4 ...

This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...

for breast cancer were updated this month to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) adjuvant therapy for patients breast cancer. According to a press ...

"The Phase III NATALEE trial demonstrated a noteworthy 25.1% reduction in the risk of recurrence among patients with HR+/HER2- stage II and III early breast cancer receiving adjuvant Kisqali ...

the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®) for breast cancer were updated to recommend ribociclib (Kisqali ®) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) adjuvant ...